Tearsheet

Edwards Lifesciences (EW)

Market Price (10/29/2025): $82.74 | Market Cap: $48.6 Bil
Sector: Health Care | Industry: Health Care Equipment

Edwards Lifesciences (EW)

Market Price (10/29/2025): $82.74
Market Cap: $48.6 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Attractive yield Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.6%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.1%	Trading close to highs Dist 52W High is 0.0%	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 29x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 61x
1	Attractive operating margins Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 28%	Weak multi-year price returns 2Y Excs Rtn is -46%, 3Y Excs Rtn is -87%
2	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 14%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 10%
3	Low stock price volatility Vol 12M is 25%

0	Attractive yield Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 8.6%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.1%
1	Attractive operating margins Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 28%
2	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 14%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 10%
3	Low stock price volatility Vol 12M is 25%
4	Trading close to highs Dist 52W High is 0.0%
5	Weak multi-year price returns 2Y Excs Rtn is -46%, 3Y Excs Rtn is -87%
6	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 29x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 61x

Market Valuation & Key Metrics

Valuation
Key Metrics

	10/29/25	2024	2023	2022	2021
Share Price CYE	$82.74	$74.03	$76.25	$74.61	$129.55
Market Cap CYE ($ Bil)	48.6	43.7	46.1	45.7	80.9
Total Debt ($ Bil)	0.7	0.7	0.7	0.7	0.7
Total Cash ($ Bil)	4.1	4.0	1.6	1.2	1.5
Enterprise Value ($ Bil)	45.2	44.4	46.8	46.4	81.6
Valuation Ratios
P/S TTM	8.5	8.1	9.2	10.3	15.4
P/EBIT TTM	29.0	28.2	33.3	30.0	46.9
P/E TTM	11.7	10.6	33.0	30.4	53.7
Sector Ratios
P/S TTM (Sector)	4.2	3.5	4.0	4.5	7.3
P/EBIT TTM (Sector)	-1.7	-1.3	-1.4	-1.3	-2.7
P/E TTM (Sector)	-2.1	-1.5	-1.5	-1.3	-2.8

	10/29/25	2024	2023
Share Price CYE	$82.74	$74.03	$76.25
Market Cap CYE ($ Bil)	48.6	43.7	46.1
Total Debt ($ Bil)	0.7	0.7	0.7
Total Cash ($ Bil)	4.1	4.0	1.6
Enterprise Value ($ Bil)	45.2	44.4	46.8
Valuation Ratios
P/S TTM	8.5	8.1	9.2
P/EBIT TTM	29.0	28.2	33.3
P/E TTM	11.7	10.6	33.0
Sector Ratios
P/S TTM (Sector)	4.2	3.5	4.0
P/EBIT TTM (Sector)	-1.7	-1.3	-1.4
P/E TTM (Sector)	-2.1	-1.5	-1.5

	EW	S&P 500
REVENUE GROWTH	FAIR
Rev LTM ($ Bil)	5.7
Rev Chg Q	11.9%	6.4%
Rev Chg LTM	9.1%	5.3%
Rev Chg 3Y Avg	3.0%	5.4%
PROFITABILITY	GOOD
Op Inc LTM ($ Bil)	1.6
CFO LTM ($ Bil)	0.8
Net Inc LTM ($ Bil)	4.1
Op Mgn LTM	27.9%	18.7%
CFO/Rev LTM	14.0%	20.5%
Net Inc Mgn	72.9%	12.7%
VALUATION	HIGH
P/S	8.5	3.3
P/CFO	61.1	16.1
P/FCF	84.0	21.1
P/E	11.7	24.1
STABILITY	VERY GOOD
Debt/Equity	0.01	0.21
Cash/Assets	0.30	0.07

EW Stock

Return (1M):

Factor Drivers of Stock Movement

The 2.1% change in EW stock from 7/29/2025 to 10/28/2025 was primarily driven by a 3.0% change in the company's P/E Multiple.

	7292025	10282025	Change
Stock Price ($)	80.47	82.19	2.14%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	5522.30	5685.10	2.95%
Net Income Margin (%)	75.66%	72.90%	-3.65%
P/E Multiple	11.30	11.64	2.99%
Shares Outstanding (Mil)	586.90	587.00	-0.02%
Cumulative Contribution			2.14%

LTM = Last Twelve Months as of date shown

The 7.7% change in EW stock from 4/29/2025 to 10/28/2025 was primarily driven by a 7.9% change in the company's P/E Multiple.

	4292025	10282025	Change
Stock Price ($)	76.28	82.19	7.75%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	5439.50	5685.10	4.52%
Net Income Margin (%)	76.70%	72.90%	-4.96%
P/E Multiple	10.79	11.64	7.94%
Shares Outstanding (Mil)	589.90	587.00	0.49%
Cumulative Contribution			7.75%

LTM = Last Twelve Months as of date shown

The 20.0% change in EW stock from 10/28/2024 to 10/28/2025 was primarily driven by a 158.2% change in the company's Net Income Margin (%).

	10282024	10282025	Change
Stock Price ($)	68.52	82.19	19.95%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	5209.10	5685.10	9.14%
Net Income Margin (%)	28.23%	72.90%	158.24%
P/E Multiple	28.06	11.64	-58.51%
Shares Outstanding (Mil)	602.10	587.00	2.51%
Cumulative Contribution			19.87%

LTM = Last Twelve Months as of date shown

The 16.0% change in EW stock from 10/29/2022 to 10/28/2025 was primarily driven by a 168.0% change in the company's Net Income Margin (%).

	10292022	10282025	Change
Stock Price ($)	70.87	82.19	15.97%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	5363.80	5685.10	5.99%
Net Income Margin (%)	27.20%	72.90%	168.03%
P/E Multiple	30.11	11.64	-61.34%
Shares Outstanding (Mil)	619.80	587.00	5.29%
Cumulative Contribution			15.65%

LTM = Last Twelve Months as of date shown

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
EW Return	17%	42%	-42%	2%	-3%	11%	-2%
Peers Return	3%	6%	-14%	2%	5%	5%	5%
S&P 500 Return	16%	27%	-19%	24%	23%	17%	110%
Monthly Win Rates [3]
EW Win Rate	50%	75%	33%	58%	75%	56%
Peers Win Rate	53%	43%	43%	47%	57%	56%
S&P 500 Win Rate	58%	75%	42%	67%	75%	67%
Max Drawdowns [4]
EW Max Drawdown	-33%	-14%	-47%	-17%	-22%	-9%
Peers Max Drawdown	-33%	-10%	-26%	-17%	-11%	-8%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: ABT, BSX, MDT, ZBH, BAX. See EW Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/28/2025 (YTD)

How Low Can It Go

Unique Key	Event	EW	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-52.8%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	111.8%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-35.3%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	54.5%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	156 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-20.0%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	25.1%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	106 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-32.0%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	47.0%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	194 days	1480 days

Compare to ABT, BSX, MDT, ZBH, BAX

In The Past

Edwards Lifesciences's stock fell -52.8% during the 2022 Inflation Shock from a high on 12/30/2021. A -52.8% loss requires a 111.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Edwards Lifesciences (EW)

Business Description

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Better Bets than Edwards Lifesciences (EW)

	EW	Better Performance than EW
Metric	Value	Industry (Health Care Equipment)
Rev Chg LTM	9.1%	ISRG (22.2%), BSX (21.4%), SYK (11.4%), RMD (9.8%), DXCM (9.3%)
Rev Chg 3Y Avg	3.0%	ISRG (16.3%), BSX (14.6%), SYK (10.6%), MDT (3.3%), BDX (4.1%)
Op Mgn LTM	27.9%	ISRG (29.3%), IDXX (31.1%), RMD (32.8%), UTMD (33.3%)
CFO/Rev LTM	14.0%	ABT (21.0%), ISRG (30.8%), BSX (23.2%), SYK (20.0%), MDT (20.9%)
FCF/Rev LTM	10.2%	ABT (15.7%), ISRG (23.6%), BSX (17.5%), SYK (16.9%), MDT (15.5%)
Total Yield	8.6%	CNMD (9.8%), EMBC (14.5%), UTMD (8.8%), PDEX (9.6%)

	EW	Better Performance than EW
Metric	Value	Sector (Health Care)
Rev Chg LTM	9.1%	LLY (36.8%), UNH (10.5%), ISRG (22.2%), AMGN (12.9%), BSX (21.4%)
Rev Chg 3Y Avg	3.0%	LLY (23.4%), JNJ (6.1%), UNH (11.4%), MRK (3.7%), ISRG (16.3%)
Op Mgn LTM	27.9%	LLY (43.0%), MRK (31.2%), ISRG (29.3%), GILD (37.4%), ZTS (37.5%)
CFO/Rev LTM	14.0%	LLY (20.5%), JNJ (26.3%), ABBV (33.1%), ABT (21.0%), MRK (29.1%)
FCF/Rev LTM	10.2%	JNJ (20.3%), ABBV (31.3%), ABT (15.7%), MRK (23.1%), TMO (14.3%)
Total Yield	8.6%	MRK (11.2%), PFE (12.9%), BMY (11.9%), ELV (9.3%), CNC (12.5%)

	EW	Better Performance than EW
Metric	Value	All Other Sectors
Rev Chg LTM	9.1%	NVDA (71.6%), MSFT (14.9%), GOOGL (13.1%), AMZN (10.9%), META (19.4%)
Rev Chg 3Y Avg	3.0%	NVDA (92.0%), MSFT (12.5%), GOOGL (10.2%), AMZN (11.3%), META (13.0%)
Op Mgn LTM	27.9%	NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM	14.0%	NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM	10.2%	NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), META (30.7%)
Total Yield	8.6%	XOM (9.7%), BABA (35.7%), WFC (9.2%), TM (1980.2%), CVX (9.6%)

		Best Bets In Health Care Sector
	EW	RPRX	HALO	CPRX	BMY	LNTH	PBH	MRK	PFE	EW	AVTR
What You Pay
P/E	11.6	15.1	14.2	12.5	16.0	14.5	14.4	13.3	13.0	11.6	15.0
P/EBIT	28.8	8.0	11.2	10.7	10.7	9.9	9.2	10.7	10.4	28.8	10.2
What You Get
Rev Chg Q	11.9%	7.7%	40.8%	19.4%	-5.6%	-4.1%	-6.6%	-1.9%	10.3%	11.9%	-1.1%
Rev Chg LTM	9.1%	3.0%	35.0%	28.5%	4.6%	5.7%	0.6%	1.8%	13.5%	9.1%	-2.3%
Rev Chg 3Y Avg	3.0%	0.8%	35.5%	49.9%	0.5%	34.3%	0.8%	3.7%	-12.4%	3.0%	-4.3%
FCF/Rev 3Y Avg	11.9%	113.4%	43.4%	38.9%	26.4%	26.1%	21.6%	20.9%	13.8%	11.9%	9.7%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	Edwards Lifesciences Earnings Notes
2	Better Bet Than Edwards Lifesciences Stock: RMD, GMED Deliver More	Actionable
3	Edwards Lifesciences vs ResMed: Which Stock Could Rally?	Counter-Intuitive Comparisons
4	Edwards Lifesciences Stock Up 7.3%, Buy Or Wait?	Return
5	Day 6 of Gains Streak for Edwards Lifesciences Stock with 5.5% Return (vs. 5.1% YTD) [9/30/2025]	Notification
6	Day 6 of Gains Streak for Edwards Lifesciences Stock with 5.5% Return (vs. 5.1% YTD) [9/30/2025]	Notification
7	Day 6 of Gains Streak for Edwards Lifesciences Stock with 5.5% Return (vs. 5.1% YTD) [9/30/2025]	Notification
8	Day 6 of Gains Streak for Edwards Lifesciences Stock with 5.5% Return (vs. 5.1% YTD) [9/30/2025]	Notification
9	Day 10 of Loss Streak for Edwards Lifesciences Stock with -8.2% Return (vs. 1.4% YTD) [9/16/2025]	Notification
10	Day 9 of Loss Streak for Edwards Lifesciences Stock with -7% Return (vs. 2.7% YTD) [9/15/2025]	Notification
11	ARTICLES
12	Stronger Bet Than Edwards Lifesciences Stock: RMD Delivers More		October 28th, 2025
13	ResMed vs Edwards Lifesciences: Which Is the Stronger Buy Today?		October 28th, 2025
14	EW Stock Up 5.5% after 6-Day Win Streak		October 1st, 2025
15	EW Stock Down -8.2% after 10-Day Loss Streak		September 17th, 2025
16	EW Stock Down -7% after 9-Day Loss Streak		September 16th, 2025

	Title
0	DASHBOARDS
1	Stronger Bet Than Edwards Lifesciences Stock: RMD Delivers More
2	ResMed vs Edwards Lifesciences: Which Is the Stronger Buy Today?
3	EW Stock Up 5.5% after 6-Day Win Streak
4	EW Stock Down -8.2% after 10-Day Loss Streak
5	EW Stock Down -7% after 9-Day Loss Streak
6	ARTICLES
7	Edwards Lifesciences Earnings Notes
8	Better Bet Than Edwards Lifesciences Stock: RMD, GMED Deliver More
9	Edwards Lifesciences vs ResMed: Which Stock Could Rally?
10	Edwards Lifesciences Stock Up 7.3%, Buy Or Wait?
11	Day 6 of Gains Streak for Edwards Lifesciences Stock with 5.5% Return (vs. 5.1% YTD) [9/30/2025]
12	Day 6 of Gains Streak for Edwards Lifesciences Stock with 5.5% Return (vs. 5.1% YTD) [9/30/2025]
13	Day 6 of Gains Streak for Edwards Lifesciences Stock with 5.5% Return (vs. 5.1% YTD) [9/30/2025]
14	Day 6 of Gains Streak for Edwards Lifesciences Stock with 5.5% Return (vs. 5.1% YTD) [9/30/2025]
15	Day 10 of Loss Streak for Edwards Lifesciences Stock with -8.2% Return (vs. 1.4% YTD) [9/16/2025]
16	Day 9 of Loss Streak for Edwards Lifesciences Stock with -7% Return (vs. 2.7% YTD) [9/15/2025]

Trade Ideas

Select past ideas related to EW. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	6.4%	6.4%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	4.1%	4.1%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.3%	6.3%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	16.9%	16.9%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	18.1%	18.1%	-8.0%
EW_12312022_Monopoly_xInd_xCD_Getting_Cheaper	12312022	EW	Edwards Lifesciences	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	26.4%	2.2%	-17.3%
EW_6302022_Monopoly_xInd_xCD_Getting_Cheaper	06302022	EW	Edwards Lifesciences	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-20.9%	-0.8%	-27.9%
EW_9302017_Monopoly_xInd_xCD_Getting_Cheaper	09302017	EW	Edwards Lifesciences	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	27.6%	59.3%	-7.3%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	6.4%	6.4%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	4.1%	4.1%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.3%	6.3%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	16.9%	16.9%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	18.1%	18.1%	-8.0%
EW_12312022_Monopoly_xInd_xCD_Getting_Cheaper	12312022	EW	Edwards Lifesciences	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	26.4%	2.2%	-17.3%
EW_6302022_Monopoly_xInd_xCD_Getting_Cheaper	06302022	EW	Edwards Lifesciences	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-20.9%	-0.8%	-27.9%
EW_9302017_Monopoly_xInd_xCD_Getting_Cheaper	09302017	EW	Edwards Lifesciences	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	27.6%	59.3%	-7.3%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	ARQT	Arcutis Biotherapeutics	27.0%	79.1%
2	W	Wayfair	23.2%	140.3%
3	AGYS	Agilysys	22.6%	7.1%
4	WULF	TeraWulf	16.9%	181.6%
5	INBX	Inhibrx Biosciences	16.4%	344.7%
6	LEG	Leggett & Platt	15.4%	12.2%
7	UEC	Uranium Energy	14.3%	127.7%
8	REGN	Regeneron Pharmaceuticals	11.8%	-7.7%
9	GCI	Gannett	10.6%	-19.6%
10	RAPP	Rapport Therapeutics	9.4%	63.2%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	ARE	Alexandria Real Estate Equities	-19.2%	-32.3%
2	METC	Ramaco Resources	-16.9%	179.1%
3	FSUN	Firstsun Capital Bancorp	-16.5%	-16.3%
4	CVLT	CommVault Systems	-16.3%	-3.4%
5	PMI	Picard Medical	-14.7%	6328.6%
6	OLN	Olin	-12.4%	-36.2%
7	VFC	VF	-12.2%	-30.9%
8	JBLU	JetBlue Airways	-11.9%	-47.1%
9	ZBRA	Zebra Technologies	-11.7%	-29.0%
10	EG	Everest	-11.4%	-14.4%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	82.5%	344.7%
2	DYN	Dyne Therapeutics	45.0%	3.1%
3	RNA	Avidity Biosciences	42.6%	140.5%
4	LUMN	Lumen Technologies	40.2%	89.3%
5	GTX	Garrett Motion	39.2%	96.3%
6	CLB	Core Laboratories	36.8%	-4.6%
7	VICR	Vicor	36.2%	85.5%
8	MOFG	MidWestOne Financial	32.7%	32.9%
9	W	Wayfair	31.7%	140.3%
10	GLUE	Monte Rosa Therapeutics	29.6%	79.1%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-67.9%	6328.6%
2	NTLA	Intellia Therapeutics	-48.2%	19.7%
3	ITGR	Integer	-37.0%	-48.7%
4	METC	Ramaco Resources	-32.4%	179.1%
5	UAMY	United States Antimony	-26.2%	416.4%
6	OGN	Organon	-26.2%	-54.3%
7	USAR	USA Rare Earth	-24.7%	67450.3%
8	WRLD	World Acceptance	-23.9%	21.5%
9	SMPL	Simply Good Foods	-22.2%	-49.3%
10	METCB	Ramaco Resources	-20.1%	65.2%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PRAX	Praxis Precision Medicines	280.5%	159.0%
2	INBX	Inhibrx Biosciences	112.0%	344.7%
3	DYN	Dyne Therapeutics	96.4%	3.1%
4	VICR	Vicor	85.0%	85.5%
5	NVTS	Navitas Semiconductor	78.4%	259.4%
6	LUMN	Lumen Technologies	70.6%	89.3%
7	BALY	Ballys	70.4%	8.8%
8	GLUE	Monte Rosa Therapeutics	70.0%	79.1%
9	NUVB	Nuvation Bio	66.8%	101.9%
10	RNA	Avidity Biosciences	64.0%	140.5%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PMI	Picard Medical	-53.4%	6328.6%
2	OGN	Organon	-35.7%	-54.3%
3	VG	Venture Global	-34.0%
4	ITGR	Integer	-32.8%	-48.7%
5	LENZ	LENZ Therapeutics	-31.4%	6.7%
6	FLY	Firefly Aerospace	-30.3%
7	SOC	Sable Offshore	-29.7%	-43.1%
8	BULL	Webull	-27.4%
9	NAGE	Niagen Bioscience	-26.6%
10	USNA	Usana Health Sciences	-26.5%	-43.4%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	ARQT	Arcutis Biotherapeutics	27.0%	79.1%
2	W	Wayfair	23.2%	140.3%
3	AGYS	Agilysys	22.6%	7.1%
4	WULF	TeraWulf	16.9%	181.6%
5	INBX	Inhibrx Biosciences	16.4%	344.7%
6	LEG	Leggett & Platt	15.4%	12.2%
7	UEC	Uranium Energy	14.3%	127.7%
8	REGN	Regeneron Pharmaceuticals	11.8%	-7.7%
9	GCI	Gannett	10.6%	-19.6%
10	RAPP	Rapport Therapeutics	9.4%	63.2%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	ARE	Alexandria Real Estate Equities	-19.2%	-32.3%
2	METC	Ramaco Resources	-16.9%	179.1%
3	FSUN	Firstsun Capital Bancorp	-16.5%	-16.3%
4	CVLT	CommVault Systems	-16.3%	-3.4%
5	PMI	Picard Medical	-14.7%	6328.6%
6	OLN	Olin	-12.4%	-36.2%
7	VFC	VF	-12.2%	-30.9%
8	JBLU	JetBlue Airways	-11.9%	-47.1%
9	ZBRA	Zebra Technologies	-11.7%	-29.0%
10	EG	Everest	-11.4%	-14.4%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	82.5%	344.7%
2	DYN	Dyne Therapeutics	45.0%	3.1%
3	RNA	Avidity Biosciences	42.6%	140.5%
4	LUMN	Lumen Technologies	40.2%	89.3%
5	GTX	Garrett Motion	39.2%	96.3%
6	CLB	Core Laboratories	36.8%	-4.6%
7	VICR	Vicor	36.2%	85.5%
8	MOFG	MidWestOne Financial	32.7%	32.9%
9	W	Wayfair	31.7%	140.3%
10	GLUE	Monte Rosa Therapeutics	29.6%	79.1%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-67.9%	6328.6%
2	NTLA	Intellia Therapeutics	-48.2%	19.7%
3	ITGR	Integer	-37.0%	-48.7%
4	METC	Ramaco Resources	-32.4%	179.1%
5	UAMY	United States Antimony	-26.2%	416.4%
6	OGN	Organon	-26.2%	-54.3%
7	USAR	USA Rare Earth	-24.7%	67450.3%
8	WRLD	World Acceptance	-23.9%	21.5%
9	SMPL	Simply Good Foods	-22.2%	-49.3%
10	METCB	Ramaco Resources	-20.1%	65.2%

Peer Comparisons for Edwards Lifesciences

Financials

	EW	ABT	BSX	MDT	ZBH	BAX	Median
Name	Edwards .	Abbott L.	Boston S.	Medtronic	Zimmer B.	Baxter I.
Mkt Price	82.19	126.61	100.97	93.23	101.14	22.86	97.10
Mkt Cap	48.2	220.7	149.4	119.5	20.0	11.7	83.9
Rev LTM	5,685	43,109	18,494	34,200	7,834	10,887	14,690
Op Inc LTM	1,588	7,515	3,388	6,647	1,475	398	2,488
FCF LTM	578	6,775	3,234	5,303	1,384	218	2,309
FCF 3Y Avg	599	5,972	2,114	4,964	1,173	658	1,643
CFO LTM	795	9,037	4,285	7,146	1,663	765	2,974
CFO 3Y Avg	867	8,130	3,014	6,625	1,512	1,166	2,263

Growth & Margins

	EW	ABT	BSX	MDT	ZBH	BAX	Median
Name	Edwards .	Abbott L.	Boston S.	Medtronic	Zimmer B.	Baxter I.
Rev Chg LTM	9.1%	5.9%	21.4%	5.0%	4.1%	3.6%	5.4%
Rev Chg 3Y Avg	3.0%	-1.5%	14.6%	3.3%	4.3%	-5.7%	3.1%
Rev Chg Q	11.9%	7.4%	22.8%	8.4%	7.0%	4.3%	7.9%
QoQ Delta Rev Chg LTM	2.9%	1.8%	5.4%	2.0%	1.8%	1.1%	1.9%
Op Mgn LTM	27.9%	17.4%	18.3%	19.4%	18.8%	3.7%	18.6%
Op Mgn 3Y Avg	29.5%	16.2%	17.6%	18.6%	19.2%	2.9%	18.1%
QoQ Delta Op Mgn LTM	0.2%	0.6%	-0.2%	-0.1%	-0.4%	0.1%	0.0%
CFO/Rev LTM	14.0%	21.0%	23.2%	20.9%	21.2%	7.0%	20.9%
CFO/Rev 3Y Avg	17.2%	19.6%	18.8%	20.2%	20.1%	11.2%	19.2%
FCF/Rev LTM	10.2%	15.7%	17.5%	15.5%	17.7%	2.0%	15.6%
FCF/Rev 3Y Avg	11.9%	14.4%	13.1%	15.1%	15.5%	6.3%	13.7%

Valuation

	EW	ABT	BSX	MDT	ZBH	BAX	Median
Name	Edwards .	Abbott L.	Boston S.	Medtronic	Zimmer B.	Baxter I.
Mkt Cap	48.2	220.7	149.4	119.5	20.0	11.7	83.9
P/S	8.5	5.1	8.1	3.5	2.6	1.1	4.3
P/EBIT	28.8	26.2	44.9	18.7	16.2	366.5	27.5
P/E	11.6	15.8	59.7	25.6	24.3	-75.7	20.0
P/CFO	60.7	24.4	34.9	16.7	12.0	15.3	20.6
Total Yield	8.6%	8.1%	1.7%	6.9%	5.1%	2.7%	6.0%
Dividend Yield	0.0%	1.8%	0.0%	3.0%	1.0%	4.0%	1.4%
FCF Yield 3Y Avg	1.1%	3.0%	1.8%	4.5%	5.3%	3.5%	3.2%
D/E	0.0	0.1	0.1	0.2	0.4	0.8	0.2
Net D/E	-0.1	0.0	0.1	0.2	0.4	0.7	0.1

Returns

	EW	ABT	BSX	MDT	ZBH	BAX	Median
Name	Edwards .	Abbott L.	Boston S.	Medtronic	Zimmer B.	Baxter I.
1M Rtn	7.8%	-4.8%	2.8%	-1.1%	3.0%	4.0%	2.9%
3M Rtn	2.1%	-0.7%	-5.2%	1.6%	6.8%	-20.2%	0.5%
6M Rtn	7.7%	-2.1%	-1.7%	12.0%	-1.1%	-25.3%	-1.4%
12M Rtn	20.0%	13.1%	19.1%	6.3%	-1.5%	-35.1%	9.7%
3Y Rtn	16.0%	34.9%	133.9%	18.6%	-8.6%	-55.0%	17.3%
1M Excs Rtn	3.0%	-7.9%	0.6%	-4.2%	-0.5%	-1.3%	-0.9%
3M Excs Rtn	-7.0%	-9.4%	-13.7%	-5.8%	0.3%	-26.2%	-8.2%
6M Excs Rtn	-16.2%	-26.0%	-25.6%	-12.0%	-25.0%	-49.2%	-25.3%
12M Excs Rtn	-1.8%	-7.9%	0.0%	-12.8%	-20.4%	-55.0%	-10.3%
3Y Excs Rtn	-86.7%	-42.4%	65.3%	-59.9%	-87.0%	-139.7%	-73.3%

Comparison Analyses

	Title
0	How Does Edwards Lifesciences Stock Stack Up Against Its Peers?
1	Edwards Lifesciences vs. Abbott Laboratories: Neither Seems Like A Good Bet
2	EW Looks Stronger Than MDT With 18% Return Potential
3	BSX Could Deliver 40% Returns And Outperform EW
4	ZBH Could Deliver 20% Returns And Outperform EW
5	Edwards Lifesciences vs. Baxter: With Return Forecast Of 49%, Edwards Lifesciences Is A Better Bet
6	Edwards Lifesciences vs. Roper Technologies: With Return Forecast Of 26%, Edwards Lifesciences Is A Better Bet
7	Edwards Lifesciences vs. Cigna: Both Seem Similar Bets
8	Edwards Lifesciences vs. Southern: With Return Forecast Of 19%, Edwards Lifesciences Is A Better Bet
9	Edwards Lifesciences vs. 3M Company: With Return Forecast Of 21%, Edwards Lifesciences Is A Better Bet

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	6/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	8/6/2025	2/28/2025	2/12/2024	2/13/2023	2/14/2022	2/12/2021	2/14/2020
Key Financials
Total Revenue	5,685	5,440	5,010	4,464	5,232	4,386	4,348
EBITDA	1,828	1,723	1,535	1,678	1,855	1,040	1,276
Operating Income	1,588	1,480	1,486	1,539	1,587	1,317	1,239
Net Income	4,144	4,175	1,402	1,522	1,503	823	1,047
EPS	6.97	6.98	2.31	2.46	2.41	1.32	1.68
Growth Rates
Total Revenue Growth	9.1%	8.6%	12.2%	-14.7%	19.3%	0.9%	16.8%
EBITDA Growth	20.8%	12.3%	-8.5%	-9.5%	78.4%	-18.6%	46.9%
Operating Income Growth	9.0%	-0.4%	-3.4%	-3.0%	20.5%	6.3%	15.5%
Net Income Growth	181.8%	197.7%	-7.9%	1.3%	82.5%	-21.3%	45.0%
Margins
EBITDA Margin	32.2%	31.7%	30.6%	37.6%	35.5%	23.7%	29.4%
Operating Income Margin	27.9%	27.2%	29.7%	34.5%	30.3%	30.0%	28.5%
Net Income Margin	72.9%	76.7%	28.0%	34.1%	28.7%	18.8%	24.1%
Cash & Debt
Total Cash	4,062	3,976	1,633	1,215	1,467	1,403	1,517
Total Debt	703	700	685	691	690	695	679
Net Debt / (Cash)	-3,360	-3,276	-948	-524	-776	-708	-838
Cash Flows
Net Cash from Operations	795	542	896	1,218	1,732	1,054	1,183
Free Cash from Operations	578	260	630	953	1,402	647	904
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	1,265	1,159	880	1,727	513	625	263

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/6/2025	5/6/2025	2/28/2025	11/6/2024	7/31/2024	4/29/2024	2/12/2024	10/27/2023	7/28/2023	4/28/2023	2/13/2023	10/28/2022
Key Financials Quarterly
Total Revenue	1,532	1,413	1,386	1,354	1,369	1,330	1,266	1,243	1,296	1,460	430	1,319
Ebitda	469	446	484	429	414	396	297	405	421	468	232	490
Operating Income	431	410	353	394	375	358	357	368	384	433	197	454
Net Income	330	358	386	3,071	364	352	370	385	307	340	398	344
EPS	0.57	0.61	0.65	5.14	0.61	0.58	0.61	0.63	0.51	0.56	0.65	0.55
Key Financials TTM
Total Revenue TTM	5,685	5,522	5,440	5,320	5,209	5,135	5,265	4,428	4,504	4,582	4,464	5,364
Ebitda TTM	1,828	1,773	1,723	1,537	1,513	1,519	1,591	1,526	1,610	1,668	1,678	1,976
Operating Income TTM	1,588	1,532	1,480	1,484	1,457	1,467	1,542	1,382	1,468	1,529	1,539	1,705
Net Income TTM	4,144	4,178	4,172	4,156	1,470	1,414	1,402	1,431	1,390	1,489	1,522	1,459
Growth Rates Quarterly
Total Revenue Growth	11.9%	6.2%	9.4%	8.9%	5.7%	-8.9%	194.6%	-5.7%	-5.7%	8.8%	-67.7%	0.7%
EBITDA Growth	13.2%	12.6%	62.8%	5.9%	-1.5%	-15.3%	28.0%	-17.3%	-12.2%	-2.1%	-56.2%	14.0%
Operating Income Growth	15.0%	14.5%	-1.0%	7.1%	-2.6%	-17.3%	81.0%	-19.0%	-13.5%	-2.3%	-45.8%	14.7%
Net Income Growth	-9.3%	1.7%	4.2%	697.8%	18.4%	3.3%	-7.2%	12.1%	-24.4%	-8.9%	18.8%	1.0%
Margins Quarterly
EBITDA Margin	30.6%	31.6%	34.9%	31.7%	30.2%	29.8%	23.5%	32.6%	32.5%	32.0%	54.0%	37.1%
Operating Income Margin	28.1%	29.0%	25.5%	29.1%	27.4%	26.9%	28.2%	29.6%	29.7%	29.6%	45.8%	34.4%
Net Income Margin	21.5%	25.3%	27.8%	226.7%	26.6%	26.5%	29.2%	31.0%	23.7%	23.3%	92.7%	26.0%
Cash & Debt
Total Cash	4,062	3,898	3,976	4,446	1,990	1,698	1,633	1,864	1,509	1,254	1,215	1,739
Total Debt	703	699	700	707	693	699	685	691	684	688	691	687
Net Debt / (Cash)	-3,360	-3,199	-3,276	-3,739	-1,297	-998	-948	-1,173	-825	-566	-524	-1,052
Cash Flows Quarterly
FCF from Operations	290	280	-128	352	372	-54	137	412	34	314	283	310
Cash Flows TTM
FCF from Operations TTM	795	876	542	806	866	528	896	1,042	940	1,239	1,218	1,309
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	6	259	100	901	158	0	448	174	8	249	866	100
Return on Invested Capital (ROIC) Quarterly
ROIC	-	-	-	-	-	-	-	-	-	-	-	-
Return on Invested Capital (ROIC) TTM
ROIC TTM	-	-	-	-	-	-	-	-	-	-	-	-

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Transcatheter Aortic Valve Replacement	3,880	3,518	3,422	2,857	2,738
Surgical Structural Heart	933	830	889	762	842
Transcatheter Mitral and Tricuspid Therapies	198	116	86	42	28
Critical Care			835	725	740
Total	5,010	4,464	5,232	4,386	4,348

Price Behavior

Price Behavior

Market Price	$82.19
Market Cap ($ Bil)	48.2
First Trading Date	03/27/2000
Distance from 52W High	0.0%
	50 Days	200 Days
DMA Price	$77.42	$74.96
DMA Trend	indeterminate	down
Distance from DMA	6.2%	9.6%
	3M	1YR
Volatility	20.9%	24.7%
Downside Capture	-3.86	47.53
Upside Capture	7.81	56.98
Correlation (SPY)	11.8%	41.1%

EW Betas & Captures as of 9/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	-0.73	-0.13	0.17	0.50	0.52	0.70
Up Beta	0.09	0.27	0.24	0.50	0.50	0.57
Down Beta	-2.35	-0.32	-0.36	0.47	0.50	0.61
Up Capture	-86%	-24%	19%	41%	48%	40%
Bmk +ve Days	13	23	35	74	144	420
Stock +ve Days	8	21	31	64	123	371
Down Capture	-33%	-19%	42%	57%	64%	99%
Bmk -ve Days	8	19	29	52	107	330
Stock -ve Days	13	21	32	60	125	376

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	10152025
Short Interest: Shares Quantity	7,787,459
Short Interest: % Change Since 9302025	4.4%
Average Daily Volume	4,052,352
Days-to-Cover Short Interest	1.92
Basic Shares Quantity	587,000,000
Short % of Basic Shares	1.3%

Returns Analyses

	Title
0	Edwards Lifesciences Stock Up 7.3%, Buy Or Wait?
1	Edwards Lifesciences During 2008 Recession vs. 2022 Inflation Shock: EW Stock Has 71% Upside If It Recovers To Pre-Inflation Shock Levels
2	EW YTD Stock Return Of 23% Outperforms ABT by 21% and Outperforms BSX by 5.1%
3	EW YTD Stock Return Of -25% Outperforms BAX by 5.7% and Underperforms BSX by -26%
4	Edwards Lifesciences Stock Return Comparison

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
7/24/2025	5.5%	4.6%	8.0%
4/23/2025	6.6%	7.1%	6.1%
2/11/2025	6.9%	5.3%	-4.2%
10/24/2024	-1.4%	-4.7%	0.2%
4/25/2024	-1.8%	-3.4%	-0.0%
2/6/2024	-1.9%	-2.3%	6.3%
10/25/2023	-8.1%	-6.6%	-0.6%
7/26/2023	-9.8%	-12.3%	-18.1%
...
SUMMARY STATS
# Positive	11	12	11
# Negative	12	11	12
Median Positive	1.6%	4.1%	4.6%
Median Negative	-5.8%	-4.7%	-6.1%
Max Positive	6.9%	7.3%	8.0%
Max Negative	-17.9%	-20.4%	-18.1%

	Forward Returns
7/24/2025	5.5%	4.6%	8.0%
4/23/2025	6.6%	7.1%	6.1%
2/11/2025	6.9%	5.3%	-4.2%
10/24/2024	-1.4%	-4.7%	0.2%
4/25/2024	-1.8%	-3.4%	-0.0%
2/6/2024	-1.9%	-2.3%	6.3%
10/25/2023	-8.1%	-6.6%	-0.6%
7/26/2023	-9.8%	-12.3%	-18.1%
4/26/2023	-0.8%	0.8%	-6.6%
1/31/2023	6.2%	4.4%	4.6%
10/27/2022	-17.9%	-20.4%	-12.2%
7/28/2022	-6.3%	-2.3%	-15.0%
4/26/2022	-5.6%	-8.9%	-16.7%
1/26/2022	-6.1%	3.9%	4.1%
10/27/2021	0.4%	1.0%	-5.6%
7/29/2021	0.6%	2.8%	4.3%
4/20/2021	6.3%	7.3%	1.2%
1/27/2021	-1.7%	-1.2%	-2.1%
10/22/2020	1.3%	-8.2%	6.5%
7/23/2020	1.0%	2.1%	1.8%
4/23/2020	1.1%	-1.6%	-1.0%
1/30/2020	-6.0%	1.1%	-9.0%
10/23/2019	1.6%	6.2%	7.8%
SUMMARY STATS
# Positive	11	12	11
# Negative	12	11	12
Median Positive	1.6%	4.1%	4.6%
Median Negative	-5.8%	-4.7%	-6.1%
Max Positive	6.9%	7.3%	8.0%
Max Negative	-17.9%	-20.4%	-18.1%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	8062025	10-Q 6/30/2025
3312025	5062025	10-Q 3/31/2025
12312024	2282025	10-K 12/31/2024
9302024	11062024	10-Q 9/30/2024
6302024	7312024	10-Q 6/30/2024
3312024	4292024	10-Q 3/31/2024
12312023	2122024	10-K 12/31/2023
9302023	10272023	10-Q 9/30/2023
6302023	7282023	10-Q 6/30/2023
3312023	4282023	10-Q 3/31/2023
12312022	2132023	10-K 12/31/2022
9302022	10282022	10-Q 9/30/2022
6302022	7292022	10-Q 6/30/2022
3312022	4282022	10-Q 3/31/2022
12312021	2142022	10-K 12/31/2021
9302021	10292021	10-Q 9/30/2021

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Chopra Daveen	CVP, TMTT	8252025	Sell	81.95	2,500	204,865	2,539,998	Form
1	Lippis Daniel J.	CVP, JAPAC	7282025	Sell	79.46	4,114	326,900	1,748,283	Form
2	Zovighian Bernard J	CEO	6032025	Sell	77.21	16,099	1,243,065	738,438	Form
3	BOBO DONALD E JR	CVP,Strategy/Corp Development	6022025	Sell	77.40	2,570	198,911	3,897,452	Form
4	Chopra Daveen	CVP, TMTT	5222025	Sell	75.08	1,500	112,612	2,514,712	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Health Care Equipment Resources

MedTech Dive

MassDevice

Fierce Medical Devices

Medical Device and Diagnostic Industry

MD+DI

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Edwards Lifesciences (EW)

Market Price (10/29/2025): $82.74 | Market Cap: $48.6 BilSector: Health Care | Industry: Health Care Equipment

Edwards Lifesciences (EW)

Market Price (10/29/2025): $82.74Market Cap: $48.6 BilSector: Health CareIndustry: Health Care Equipment

Market Valuation & Key Metrics

EW Stock

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Edwards Lifesciences (EW)

Interactive Breakdown

Better Bets than Edwards Lifesciences (EW)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Edwards Lifesciences

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (10/29/2025): $82.74 | Market Cap: $48.6 Bil
Sector: Health Care | Industry: Health Care Equipment

Market Price (10/29/2025): $82.74
Market Cap: $48.6 Bil
Sector: Health Care
Industry: Health Care Equipment